{"id":"W4240962932","doi":"10.1093/neuonc/nox036.076","title":"OS11.5 ACT IV: An international, double-blind, phase 3 trial of rindopepimut in newly diagnosed, EGFRvIII-expressing glioblastoma","year":2017,"lang":"en","type":"article","venue":"Neuro-Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Temozolomide; Interim analysis; Hazard ratio; Internal medicine; Oncology; Cohort; Clinical endpoint; Confidence interval; Randomized controlled trial; Chemotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003157609,0.0002643013,0.0007497772,0.0003875711,0.0001524315,0.0000819995,0.0004953648,0.0002496228,0.0002115987],"category_scores_gemma":[0.000542087,0.0002323695,0.0001813575,0.0001058373,0.0002051219,0.0004202058,0.0001967768,0.0003412491,0.00003945639],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002193859,"about_ca_system_score_gemma":0.0003054516,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003577922,"about_ca_topic_score_gemma":0.0005959959,"domain_scores_codex":[0.9979144,0.000156027,0.0006428232,0.0005496326,0.0003585856,0.0003785366],"domain_scores_gemma":[0.9976352,0.0004270755,0.000590024,0.000950732,0.0001444254,0.0002525068],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.4641125,0.02642711,0.07026736,0.00004853947,0.0002890387,0.008534227,0.0009347453,0.00008462077,0.2476633,0.0004224725,0.001289929,0.1799262],"study_design_scores_gemma":[0.8263351,0.0157107,0.0163005,0.0001277349,0.0002238366,0.0001780904,0.0001091635,0.000354338,0.0941981,0.00005489436,0.04616674,0.0002408515],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9867195,0.00005667378,0.000005069156,0.002874656,0.001791922,0.001328795,0.00002018722,0.00003988508,0.007163269],"genre_scores_gemma":[0.9982037,0.0001868003,0.0002079592,0.0004010536,0.0006327012,0.000275327,0.00003374898,0.00004053693,0.00001815762],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3622226,"threshold_uncertainty_score":0.9475753,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0690954306968465,"score_gpt":0.4028926386686069,"score_spread":0.3337972079717604,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}